Abstract:Wei-Ying Diao, 1, &ast Cheng-Long Ding, 1, &ast Bo-Yang Yuan, 2 Zan Li, 3 Na Sun, 4 Jia-Bin Huang 5 1 Department of Pathology, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 2 Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People's Republic of China; 3 Department of Analytical Chemistry Teaching and Research, Jiamusi University, Jiamusi City, Heilongjiang Province, 154002, People's Republic of China; 4 Graduate Department, Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China; 5 Department of Geratology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jia-Bin Huang Email Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients. Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared. Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes ( P 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients ( P < 0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group ( P < 0.05). Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB∼IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients. Keywords: non-small cell lung cancer, HER2 genotype, CT signs, afatinib As one of the most prevalent malignant tumors worldwide, lung cancer has become the top cause of cancer-related death in the urban population of China. Non-small cell lung cancer (NSCLC) includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, in which cancer cells grow and divide more slowly, and spread and metastasize are less drastic. 1,2 NSCLC accounts for about 80% of overall lung cancers, and approximately 75% of patients have progressed in the advanced stage when diagnosed, with somber 5-year survival rate. 3 At present, the treatment of NSCLC mainly includes surgery, radiotherapy, chemotherapy, immunotherapy, etc. A large number of studies have shown that the occurrence and development of lung cancer are consequent to the unbalanced regulation of multiple gene expression, which is closely related to the stability of genes in organisms. 4,5 Human Epithelial Factor Receptor-2 (HER2) is a member of the epithelial factor receptor family. Studies demonstrated that HER2 overexpression is an enhancer of EGFR signaling, and it plays a role in signal transduction in cancer development and progress when HER2 is dysfunctional. 6 Afatinib and trezizumab have been recommended as targeted therapies for patients with HER2 mutation -Abstract Truncated-

MA08.09 Clinical Management of Lung Adenocarcinoma Patients with HER2 V659E Mutation

Clinical Management of Lung Adenocarcinoma Patients with HER2 V659E Mutation.

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

HER2 Transmembrane Domain Mutation: Comprehensive Characteristics and Real-World Evidence of Treatment Response in Chinese Lung Adenocarcinoma.

HER-2 Mutations in Chinese Lung Adenocarcinoma Patients with Negative EGFR Mutations.

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

Ado-trastuzumab Emtansine in the Treatment of Lung Adenocarcinoma with ERBB2 Mutation: a Case Report and Literature Review

P1.03-045 HER-2 Mutation is Not a Prognostic Factor Treated with First-Line Chemotherapy in NSCLC Patients

EP11.03-19 Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 Exon 20 Insertion Mutations

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer

HER2-Activating Missense Mutations in Advanced Non-Small Cell Lung Cancer: Rare but Targetable Spot Should Not Be Neglected

The Efficacy of Ado-Trastuzumab Emtansine in Patients with HER-2-aberrant Non-Small Cell Lung Cancer.

Combination therapy with afatinib and bevacizumab in an <i>EGFR</i>-mutated non-small cell lung cancer patient with acquired ERBB2 amplification A case report

P1.02-046 Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains

A Narrative Review of Advances in Treatment and Survival Prognosis of HER2-positive Malignant Lung Cancers

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

P1.01-110 Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated with Afatinib

The Efficacy of Ado-trastuzumab Emtansine in HER-2 Aberrant Non-Small Cell Lung Cancer